BioMarin Pharmaceutical vs Fortrea
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put BioMarin Pharmaceutical and Fortrea side by side, using each oneβs latest annual report. Here is what stands out:
- BioMarin Pharmaceutical is the larger business, with $3.2B of revenue in fiscal 2025 against $2.7B for Fortrea.
- BioMarin Pharmaceutical grew revenue faster (12.9%, against 1.0%).
- BioMarin Pharmaceutical kept more of each dollar of sales as operating profit (12.7% operating margin, against β32.0%).
- BioMarin Pharmaceutical turned more of its sales into free cash flow (22.5% FCF margin, against 3.2%).
- BioMarin Pharmaceutical earned a higher return on the capital invested in it (5.8%, against β36.2%).
Who comes out ahead
Of the 6 measures where higher (or lower) is clearly better, how many each company leads.
BioMarin Pharmaceutical
BMRN
6/6
Revenue growthOperating marginNet marginFCF marginReturn on capitalReturn on equity
Fortrea
FTRE
0/6
Side by side
Best in the row
| Latest fiscal year | BMRN FY25 | FTRE FY25 |
|---|---|---|
| Size | ||
| Market cap | $10.8B | $2.3B |
| Revenue | $3.2B | $2.7B |
| Free cash flow | $725M | $88.3M |
| Net income | $349M | β$986M |
| Growth | ||
| Revenue growth | 12.9% | 1.0% |
| 5-year growth | 11.6% | β |
| Share count change | 0.4% | β |
| Profitability | ||
| Gross margin | 77.7% | β |
| Operating margin | 12.7% | β32.0% |
| Net margin | 10.8% | β36.2% |
| FCF margin | 22.5% | 3.2% |
| Return on capital | 5.8% | β36.2% |
| Return on equity | 5.9% | β102.4% |
| Balance sheet | ||
| Net debt | β$963M | $878M |
| Net debt / EBITDA | β2.0x | β |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | 150.7x | β |
| Piotroski F-score | 5 | β |
Ten years
Revenue
FY16
BMRN $1.1B
FTRE β
FY17
BMRN $1.3B
FTRE β
FY18
BMRN $1.5B
FTRE β
FY19
BMRN $1.7B
FTRE β
FY20
BMRN $1.9B
FTRE β
FY21
BMRN $1.8B
FTRE $3.1B
FY22
BMRN $2.1B
FTRE $2.8B
FY23
BMRN $2.4B
FTRE $2.8B
FY24
BMRN $2.9B
FTRE $2.7B
FY25
BMRN $3.2B
FTRE $2.7B
BMRN
FTRE
Operating margin
FY16
BMRN β71.9%
FTRE β
FY17
BMRN β1.1%
FTRE β
FY18
BMRN β8.3%
FTRE β
FY19
BMRN β5.9%
FTRE β
FY20
BMRN β2.3%
FTRE β
FY21
BMRN β4.5%
FTRE 3.7%
FY22
BMRN 7.7%
FTRE 6.6%
FY23
BMRN 7.7%
FTRE 1.1%
FY24
BMRN 17.0%
FTRE β6.0%
FY25
BMRN 12.7%
FTRE β32.0%
BMRN
FTRE
Free cash flow
FY16
BMRN β$376M
FTRE β
FY17
BMRN β$208M
FTRE β
FY18
BMRN β$124M
FTRE β
FY19
BMRN β$96.8M
FTRE β
FY20
BMRN β$29.0M
FTRE β
FY21
BMRN $209M
FTRE $143M
FY22
BMRN $54.9M
FTRE $28.3M
FY23
BMRN $62.6M
FTRE $128M
FY24
BMRN $487M
FTRE $237M
FY25
BMRN $725M
FTRE $88.3M
BMRN
FTRE
Return on capital
FY16
BMRN β24.7%
FTRE β
FY17
BMRN β0.4%
FTRE β
FY18
BMRN β3.7%
FTRE β
FY19
BMRN β2.7%
FTRE β
FY20
BMRN β0.9%
FTRE β
FY21
BMRN β1.5%
FTRE β
FY22
BMRN 3.5%
FTRE β
FY23
BMRN 3.5%
FTRE 0.8%
FY24
BMRN 7.6%
FTRE β4.6%
FY25
BMRN 5.8%
FTRE β36.2%
BMRN
FTRE
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.